Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Intrahost evolutionary dynamics of canine influenza virus in naive and partially immune dogs.

Hoelzer K, Murcia PR, Baillie GJ, Wood JL, Metzger SM, Osterrieder N, Dubovi EJ, Holmes EC, Parrish CR.

J Virol. 2010 May;84(10):5329-35. doi: 10.1128/JVI.02469-09. Epub 2010 Mar 10.

2.

Delivery of foreign antigens by engineered outer membrane vesicle vaccines.

Chen DJ, Osterrieder N, Metzger SM, Buckles E, Doody AM, DeLisa MP, Putnam D.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3099-104. doi: 10.1073/pnas.0805532107. Epub 2010 Jan 27.

3.

A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus.

Van de Walle GR, May MA, Peters ST, Metzger SM, Rosas CT, Osterrieder N.

Vaccine. 2010 Jan 22;28(4):1048-55. doi: 10.1016/j.vaccine.2009.10.123. Epub 2009 Nov 6.

PMID:
19897066
4.

Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza.

Rosas C, Van de Walle GR, Metzger SM, Hoelzer K, Dubovi EJ, Kim SG, Parrish CR, Osterrieder N.

Vaccine. 2008 May 2;26(19):2335-43. doi: 10.1016/j.vaccine.2008.02.064. Epub 2008 Mar 31.

5.

Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1).

Goodman LB, Wagner B, Flaminio MJ, Sussman KH, Metzger SM, Holland R, Osterrieder N.

Vaccine. 2006 Apr 24;24(17):3636-45. Epub 2006 Feb 13.

PMID:
16513225

Supplemental Content

Loading ...
Support Center